InhaleRx (ASX:IRX) formally executed a study order with iNGENu CRO as the contract research organization to oversee its phase one clinical trial of IRX-616a, a drug candidate for panic disorder, according to a Thursday Australian bourse filing.
The study is a randomized, double-blind, placebo-controlled, single ascending dose trial seeking to evaluate the pharmacokinetics, safety, and tolerability of the IRX-616a cannabidiol inhaler in healthy volunteers, the filing said.
The firm plans to procure the manufacturing of the drug candidate and finalize all documentation for a human research ethics committee approval, per the filing.
InhaleRx's shares jumped over 22% in recent trading on Thursday, earlier hitting an all-time low.
Price (AUD): $0.02, Change: $+0.0040, Percent Change: +22.22%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.